l General Information |
Product Name | VX-809 (Lumacaftor) |
General description | Lumacaftor acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation. |
Synonym | 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid; VRT 826809 |
Purity | ≥98.0%(HPLC) | CAS Number | 936727-05-8 |
Formula | C24H18F2N2O5 | Molecular Weight | 452.41 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥5mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Lumacaftor acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
